| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| nejm breast cancer review | 0.87 | 1 | 6205 | 59 | 25 |
| nejm | 1.79 | 0.4 | 2039 | 24 | 4 |
| breast | 1.13 | 1 | 2165 | 73 | 6 |
| cancer | 1.89 | 1 | 1817 | 80 | 6 |
| review | 1.65 | 0.4 | 2369 | 55 | 6 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| nejm breast cancer review | 1.96 | 0.2 | 4865 | 39 |
| nejm 20 year breast cancer | 0.15 | 0.1 | 7693 | 61 |
| nejm risk of breast cancer recurrence | 0.93 | 1 | 5093 | 29 |
| nejm lung cancer review | 0.88 | 1 | 3993 | 37 |
| olaparib breast cancer nejm | 1.98 | 0.1 | 4910 | 98 |
| breast cancer review journal | 1.09 | 0.8 | 6267 | 36 |
| abemaciclib adjuvant breast cancer nejm | 1.16 | 0.8 | 412 | 63 |
| nejm evidence vs nejm | 0.67 | 0.8 | 7662 | 37 |
| breast cancer treatment review article | 0.58 | 0.7 | 6349 | 86 |
| nejm out for review | 1.64 | 0.9 | 102 | 47 |
| breast cancer review article | 1.67 | 0.4 | 5525 | 23 |
| study published in the journal nejm | 0.89 | 0.7 | 9631 | 92 |
| head and neck cancer review nejm | 1.43 | 0.7 | 3249 | 60 |
| breast cancer systematic review | 1.65 | 0.8 | 1465 | 62 |
| new england journal of medicine nejm | 1.05 | 0.6 | 3544 | 90 |
| nejm pembrolizumab endometrial cancer | 0.45 | 0.8 | 2503 | 37 |
| nejm lung cancer screening | 0.76 | 0.7 | 2362 | 68 |
| nejm 365 22 december 1 2011 | 0.83 | 0.7 | 3153 | 89 |
| nejm im board review | 1.35 | 0.6 | 1360 | 100 |
| journals similar to nejm | 1.46 | 0.8 | 9253 | 51 |
| what is the nejm | 0.37 | 0.5 | 5487 | 43 |
| nejm lancet jama bmj | 1.35 | 0.4 | 8398 | 99 |
| nejm case free article | 1.2 | 0.3 | 8536 | 77 |
